Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 5-6/2016

01-12-2016 | Review

HIV infection: focus on the innate immune cells

Authors: Milena S. Espíndola, Luana S. Soares, Leonardo J. Galvão-Lima, Fabiana A. Zambuzi, Maira C. Cacemiro, Verônica S. Brauer, Fabiani G. Frantz

Published in: Immunologic Research | Issue 5-6/2016

Login to get access

Abstract

Innate immune cells play a critical role during the onset of HIV infection and remain active until the final events that characterize AIDS. The viral impact on innate immune cell response may be a result of direct infection or indirect modulation, and each cell type responds in a specific manner to HIV. During HIV infection, the immune system works in a dynamic way, where innate and adaptive cells contribute with each other stimulating their function and modulating phenotypes and consequently infection resolution. Understanding the alterations in the cell populations induced by the virus is pivotal and can help to combat HIV at the time of infection and above all, to prevent the establishment of viral reservoirs. In this review, we will describe the frequency and the subtypes of infected cells such as of monocytes, DCs, neutrophils, eosinophils, mast cells/basophils, NK cells, NKT cells and γδ T cells, and we discuss the possibility of cell-targeting strategies. Our aim is to consolidate the existing knowledge of the interaction between HIV and cells that constitute the innate immune response.
Literature
1.
Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol. 2003;1(1):25–34.PubMedCrossRef
2.
Zhang Z, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science. 1999;286(5443):1353–7.PubMedCrossRef
3.
4.
5.
Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 2000;100(5):587–97.PubMedCrossRef
6.
Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009;325(5940):612–6.PubMedPubMedCentralCrossRef
7.
van Furth R, Sluiter W. Distribution of blood monocytes between a marginating and a circulating pool. J Exp Med. 1986;163(2):474–9.PubMedCrossRef
8.
Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116(16):e74–80.PubMedCrossRef
9.
Yang J, Zhang L, Yu C, Yang XF, Wang H. Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res. 2014;2(1):1.PubMedPubMedCentralCrossRef
10.
Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol. 2014;14(6):392–404.PubMedCrossRef
11.
12.
Sonza S, Mutimer HP, Oelrichs R, Jardine D, Harvey K, Dunne A, et al. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS. 2001;15(1):17–22.PubMedCrossRef
13.
Hasegawa A, Liu H, Ling B, Borda JT, Alvarez X, Sugimoto C, et al. The level of monocyte turnover predicts disease progression in the macaque model of AIDS. Blood. 2009;114(14):2917–25.PubMedPubMedCentralCrossRef
14.
Williams KC, Hickey WF. Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Ann Rev Neurosci. 2002;25:537–62.PubMedCrossRef
15.
Burdo TH, Soulas C, Orzechowski K, Button J, Krishnan A, Sugimoto C, et al. Increased monocyte turnover from bone marrow correlates with severity of SIV encephalitis and CD163 levels in plasma. PLoS Pathog. 2010;6(4):e1000842.PubMedPubMedCentralCrossRef
16.
Thieblemont N, Weiss L, Sadeghi HM, Estcourt C, Haeffner-Cavaillon N. CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection. Eur J Immunol. 1995;25(12):3418–24.PubMedCrossRef
17.
Ziegler-Heitbrock HW, Fingerle G, Strobel M, Schraut W, Stelter F, Schutt C, et al. The novel subset of CD14 +/CD16 + blood monocytes exhibits features of tissue macrophages. Eur J Immunol. 1993;23(9):2053–8.PubMedCrossRef
18.
Almeida J, Bueno C, Alguero MC, Sanchez ML, de Santiago M, Escribano L, et al. Comparative analysis of the morphological, cytochemical, immunophenotypical, and functional characteristics of normal human peripheral blood lineage(−)/CD16(+)/HLA-DR(+)/CD14(−/lo) cells, CD14(+) monocytes, and CD16(−) dendritic cells. Clin Immunol. 2001;100(3):325–38.PubMedCrossRef
19.
de Baey A, Mende I, Riethmueller G, Baeuerle PA. Phenotype and function of human dendritic cells derived from M-DC8(+) monocytes. Eur J Immunol. 2001;31(6):1646–55.PubMedCrossRef
20.
Sanchez-Torres C, Garcia-Romo GS, Cornejo-Cortes MA, Rivas-Carvalho A, Sanchez-Schmitz G. CD16+ and CD16− human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells. Int Immunol. 2001;13(12):1571–81.PubMedCrossRef
21.
Siedlar M, Frankenberger M, Ziegler-Heitbrock LH, Belge KU. The M-DC8-positive leukocytes are a subpopulation of the CD14+ CD16+ monocytes. Immunobiology. 2000;202(1):11–7.PubMedCrossRef
22.
Ellery PJ, Tippett E, Chiu YL, Paukovics G, Cameron PU, Solomon A, et al. The CD16 + monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol. 2007;178(10):6581–9.PubMedCrossRef
23.
Ansari AW, Meyer-Olson D, Schmidt RE. Selective expansion of pro-inflammatory chemokine CCL2-loaded CD14+CD16+ monocytes subset in HIV-infected therapy naive individuals. J Clin Immunol. 2013;33(1):302–6.PubMedCrossRef
24.
Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis. 2011;204(1):154–63.PubMedPubMedCentralCrossRef
25.
Wilson EM, Singh A, Hullsiek KH, Gibson D, Henry WK, Lichtenstein K, et al. Monocyte activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. J Infect Dis. 2014;210(9):1396–406.PubMedPubMedCentralCrossRef
26.
Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011;204(8):1227–36.PubMedPubMedCentralCrossRef
27.
Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis. 2012;206(10):1558–67.PubMedPubMedCentralCrossRef
28.
Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780–90.PubMedPubMedCentralCrossRef
29.
Tippett E, Cameron PU, Marsh M, Crowe SM. Characterization of tetraspanins CD9, CD53, CD63, and CD81 in monocytes and macrophages in HIV-1 infection. J Leukoc Biol. 2013;93(6):913–20.PubMedCrossRef
30.
Gekonge B, Giri MS, Kossenkov AV, Nebozyhn M, Yousef M, Mounzer K, et al. Constitutive gene expression in monocytes from chronic HIV-1 infection overlaps with acute Toll-like receptor induced monocyte activation profiles. PLoS ONE. 2012;7(7):e41153.PubMedPubMedCentralCrossRef
31.
Lester RT, Yao XD, Ball TB, McKinnon LR, Kaul R, Wachihi C, et al. Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS. 2008;22(6):685–94.PubMedCrossRef
32.
Centlivre M, Legrand N, Steingrover R, van der Sluis R, Grijsen ML, Bakker M, et al. Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acute and chronic HIV-1 infection. J Leukoc Biol. 2011;89(5):785–95.PubMedCrossRef
33.
Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS. Unique monocyte subset in patients with AIDS dementia. Lancet. 1997;349(9053):692–5.PubMedCrossRef
34.
Simmons RP, Scully EP, Groden EE, Arnold KB, Chang JJ, Lane K, et al. HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathways. AIDS. 2013;27(16):2505–17.PubMedPubMedCentralCrossRef
35.
Dutertre CA, Amraoui S, DeRosa A, Jourdain JP, Vimeux L, Goguet M, et al. Pivotal role of M-DC8(+) monocytes from viremic HIV-infected patients in TNFalpha overproduction in response to microbial products. Blood. 2012;120(11):2259–68.PubMedCrossRef
36.
Manuzak JA, Dillon SM, Lee EJ, Dong ZM, Hecht DK, Wilson CC. Increased Escherichia coli-induced interleukin-23 production by CD16+ monocytes correlates with systemic immune activation in untreated HIV-1-infected individuals. J Virol. 2013;87(24):13252–62.PubMedPubMedCentralCrossRef
37.
Jiang W, Lederman MM, Salkowitz JR, Rodriguez B, Harding CV, Sieg SF. Impaired monocyte maturation in response to CpG oligodeoxynucleotide is related to viral RNA levels in human immunodeficiency virus disease and is at least partially mediated by deficiencies in alpha/beta interferon responsiveness and production. J Virol. 2005;79(7):4109–19.PubMedPubMedCentralCrossRef
38.
Saez R, Echaniz P, de Juan MD, Iribarren JA, Cuadrado E. HIV-infected progressors and long-term non-progressors differ in their capacity to respond to an A-class CpG oligodeoxynucleotide. AIDS. 2005;19(16):1924–5.PubMedCrossRef
39.
Baqui AA, Meiller TF, Zhang M, Falkler WA Jr. The effects of HIV viral load on the phagocytic activity of monocytes activated with lipopolysaccharide from oral microorganisms. Immunopharmacol Immunotoxicol. 1999;21(3):421–38.PubMedCrossRef
40.
Bravo-Cuellar A, Nowacki W, Vuillier F, de Saint-Martin J, Orbach-Arbouys S. The bactericidal capacity of peripheral blood monocytes from HIV positive patients may collapse very soon after the infection. Immunol Lett. 1992;31(3):297–9.PubMedCrossRef
41.
Cameron ML, Granger DL, Matthews TJ, Weinberg JB. Human immunodeficiency virus (HIV)-infected human blood monocytes and peritoneal macrophages have reduced anticryptococcal activity whereas HIV-infected alveolar macrophages retain normal activity. J Infect Dis. 1994;170(1):60–7.PubMedCrossRef
42.
Delemarre FG, Stevenhagen A, Kroon FP, van Eer MY, Meenhorst PL, van Furth R. Reduced toxoplasmastatic activity of monocytes and monocyte-derived macrophages from AIDS patients is mediated via prostaglandin E2. AIDS. 1995;9(5):441–5.PubMedCrossRef
43.
Dobmeyer TS, Raffel B, Dobmeyer JM, Findhammer S, Klein SA, Kabelitz D, et al. Decreased function of monocytes and granulocytes during HIV-1 infection correlates with CD4 cell counts. Eur J Med Res. 1995;1(1):9–15.PubMed
44.
Estevez ME, Ballart IJ, Diez RA, Planes N, Scaglione C, Sen L. Early defect of phagocytic cell function in subjects at risk for acquired immunodeficiency syndrome. Scand J Immunol. 1986;24(2):215–21.PubMedCrossRef
45.
Kedzierska K, Azzam R, Ellery P, Mak J, Jaworowski A, Crowe SM. Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. J Clin Virol. 2003;26(2):247–63.PubMedCrossRef
46.
Ludlow LE, Zhou J, Tippett E, Cheng WJ, Hasang W, Rogerson SJ, et al. HIV-1 inhibits phagocytosis and inflammatory cytokine responses of human monocyte-derived macrophages to P. falciparum infected erythrocytes. PLoS ONE. 2012;7(2):e32102.PubMedPubMedCentralCrossRef
47.
Michailidis C, Giannopoulos G, Vigklis V, Armenis K, Tsakris A, Gargalianos P. Impaired phagocytosis among patients infected by the human immunodeficiency virus: implication for a role of highly active anti-retroviral therapy. Clin Exp Immunol. 2012;167(3):499–504.PubMedPubMedCentralCrossRef
48.
Pos O, Stevenhagen A, Meenhorst PL, Kroon FP, Van Furth R. Impaired phagocytosis of Staphylococcus aureus by granulocytes and monocytes of AIDS patients. Clin Exp Immunol. 1992;88(1):23–8.PubMedPubMedCentralCrossRef
49.
Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001;106(3):255–8.PubMedCrossRef
50.
Klagge IM, Schneider-Schaulies S. Virus interactions with dendritic cells. J Gen Virol. 1999;80(Pt 4):823–33.PubMedCrossRef
51.
Hu J, Pope M, Brown C, O’Doherty U, Miller CJ. Immunophenotypic characterization of simian immunodeficiency virus-infected dendritic cells in cervix, vagina, and draining lymph nodes of rhesus monkeys. Lab Investig J Tech Methods Pathol. 1998;78(4):435–51.
52.
Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 1996;274(5289):985–9.PubMedCrossRef
53.
Smith BA, Gartner S, Liu Y, Perelson AS, Stilianakis NI, Keele BF, et al. Persistence of infectious HIV on follicular dendritic cells. J Immunol. 2001;166(1):690–6.PubMedCrossRef
54.
Spiegel H, Herbst H, Niedobitek G, Foss HD, Stein H. Follicular dendritic cells are a major reservoir for human immunodeficiency virus type 1 in lymphoid tissues facilitating infection of CD4+ T-helper cells. Am J Pathol. 1992;140(1):15–22.PubMedPubMedCentral
55.
van Nierop K, de Groot C. Human follicular dendritic cells: function, origin and development. Semin Immunol. 2002;14(4):251–7.PubMedCrossRef
56.
Cameron PU, Handley AJ, Baylis DC, Solomon AE, Bernard N, Purcell DF, et al. Preferential infection of dendritic cells during human immunodeficiency virus type 1 infection of blood leukocytes. J Virol. 2007;81(5):2297–306.PubMedCrossRef
57.
Masurier C, Salomon B, Guettari N, Pioche C, Lachapelle F, Guigon M, et al. Dendritic cells route human immunodeficiency virus to lymph nodes after vaginal or intravenous administration to mice. J Virol. 1998;72(10):7822–9.PubMedPubMedCentral
58.
Barratt-Boyes SM, Zimmer MI, Harshyne L. Changes in dendritic cell migration and activation during SIV infection suggest a role in initial viral spread and eventual immunosuppression. J Med Primatol. 2002;31(4–5):186–93.PubMedCrossRef
59.
Chen JJ, Huang JC, Shirtliff M, Briscoe E, Ali S, Cesani F, et al. CD4 lymphocytes in the blood of HIV(+) individuals migrate rapidly to lymph nodes and bone marrow: support for homing theory of CD4 cell depletion. J Leukoc Biol. 2002;72(2):271–8.PubMed
60.
Murooka TT, Deruaz M, Marangoni F, Vrbanac VD, Seung E, von Andrian UH, et al. HIV-infected T cells are migratory vehicles for viral dissemination. Nature. 2012;490(7419):283–7.PubMedPubMedCentralCrossRef
61.
Negre D, Mangeot PE, Duisit G, Blanchard S, Vidalain PO, Leissner P, et al. Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther. 2000;7(19):1613–23.PubMedCrossRef
62.
Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, Littman DR. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature. 2010;467(7312):214–7.PubMedPubMedCentralCrossRef
63.
64.
Turville SG, Cameron PU, Handley A, Lin G, Pohlmann S, Doms RW, et al. Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol. 2002;3(10):975–83.PubMedCrossRef
65.
Fantuzzi L, Purificato C, Donato K, Belardelli F, Gessani S. Human immunodeficiency virus type 1 gp120 induces abnormal maturation and functional alterations of dendritic cells: a novel mechanism for AIDS pathogenesis. J Virol. 2004;78(18):9763–72.PubMedPubMedCentralCrossRef
66.
Cameron PU, Forsum U, Teppler H, Granelli-Piperno A, Steinman RM. During HIV-1 infection most blood dendritic cells are not productively infected and can induce allogeneic CD4+ T cells clonal expansion. Clin Exp Immunol. 1992;88(2):226–36.PubMedPubMedCentralCrossRef
67.
Donaghy H, Gazzard B, Gotch F, Patterson S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood. 2003;101(11):4505–11.PubMedCrossRef
68.
Macatonia SE, Patterson S, Knight SC. Suppression of immune responses by dendritic cells infected with HIV. Immunology. 1989;67(3):285–9.PubMedPubMedCentral
69.
Manches O, Frleta D, Bhardwaj N. Dendritic cells in progression and pathology of HIV infection. Trends Immunol. 2014;35(3):114–22.PubMedCrossRef
70.
Roberts M, Gompels M, Pinching AJ, Knight SC. Dendritic cells from HIV-1 infected individuals show reduced capacity to stimulate autologous T-cell proliferation. Immunol Lett. 1994;43(1–2):39–43.PubMedCrossRef
71.
Macatonia SE, Lau R, Patterson S, Pinching AJ, Knight SC. Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. Immunology. 1990;71(1):38–45.PubMedPubMedCentral
72.
Pacanowski J, Kahi S, Baillet M, Lebon P, Deveau C, Goujard C, et al. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood. 2001;98(10):3016–21.PubMedCrossRef
73.
Sabado RL, O’Brien M, Subedi A, Qin L, Hu N, Taylor E, et al. Evidence of dysregulation of dendritic cells in primary HIV infection. Blood. 2010;116(19):3839–52.PubMedPubMedCentralCrossRef
74.
Behbahani H, Landay A, Patterson BK, Jones P, Pottage J, Agnoli M, et al. Normalization of immune activation in lymphoid tissue following highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;25(2):150–6.PubMedCrossRef
75.
Martin-Gayo E, Buzon MJ, Ouyang Z, Hickman T, Cronin J, Pimenova D, et al. Potent cell-intrinsic immune responses in dendritic cells facilitate HIV-1-specific T cell immunity in HIV-1 elite controllers. PLoS Pathog. 2015;11(6):e1004930.PubMedPubMedCentralCrossRef
76.
Loffredo JT, Friedrich TC, Leon EJ, Stephany JJ, Rodrigues DS, Spencer SP, et al. CD8+ T cells from SIV elite controller macaques recognize Mamu-B*08-bound epitopes and select for widespread viral variation. PLoS ONE. 2007;2(11):e1152.PubMedPubMedCentralCrossRef
77.
Walker BD, Yu XG. Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol. 2013;13(7):487–98.PubMedCrossRef
78.
Martinson JA, Roman-Gonzalez A, Tenorio AR, Montoya CJ, Gichinga CN, Rugeles MT, et al. Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. Cell Immunol. 2007;250(1–2):75–84.PubMedCrossRef
79.
Miller EA, Spadaccia MR, O’Brien MP, Rolnitzky L, Sabado R, Manches O, et al. Plasma factors during chronic HIV-1 infection impair IL-12 secretion by myeloid dendritic cells via a virus-independent pathway. J Acquir Immune Defic Syndr. 2012;61(5):535–44.PubMedPubMedCentralCrossRef
80.
Miller E, Bhardwaj N. Dendritic cell dysregulation during HIV-1 infection. Immunol Rev. 2013;254(1):170–89.PubMedCrossRef
81.
Ito T, Kanzler H, Duramad O, Cao W, Liu YJ. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood. 2006;107(6):2423–31.PubMedCrossRef
82.
O’Brien M, Manches O, Sabado RL, Baranda SJ, Wang Y, Marie I, et al. Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-alpha-producing and partially matured phenotype. J Clin Investig. 2011;121(3):1088–101.PubMedPubMedCentralCrossRef
83.
Williams MA, Trout R, Spector SA. HIV-1 gp120 modulates the immunological function and expression of accessory and co-stimulatory molecules of monocyte-derived dendritic cells. J Hematother Stem Cell Res. 2002;11(5):829–47.PubMedCrossRef
84.
Kawamura T, Gatanaga H, Borris DL, Connors M, Mitsuya H, Blauvelt A. Decreased stimulation of CD4+ T cell proliferation and IL-2 production by highly enriched populations of HIV-infected dendritic cells. J Immunol. 2003;170(8):4260–6.PubMedCrossRef
85.
Smed-Sorensen A, Lore K, Walther-Jallow L, Andersson J, Spetz AL. HIV-1-infected dendritic cells up-regulate cell surface markers but fail to produce IL-12 p70 in response to CD40 ligand stimulation. Blood. 2004;104(9):2810–7.PubMedCrossRef
86.
Garcia F, Routy JP. Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine. 2011;29(38):6454–63.PubMedCrossRef
87.
Lakschevitz FS, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342(2):200–9.PubMedCrossRef
88.
Sagiv JY, Michaeli J, Assi S, Mishalian I, Kisos H, Levy L, et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 2015;10(4):562–73.PubMedCrossRef
89.
Mayadas TN, Cullere X, Lowell CA. The multifaceted functions of neutrophils. Ann Rev Pathol. 2014;9:181–218.CrossRef
90.
Donahue RE, Johnson MM, Zon LI, Clark SC, Groopman JE. Suppression of in vitro haematopoiesis following human immunodeficiency virus infection. Nature. 1987;326(6109):200–3.PubMedCrossRef
91.
Pitrak DL, Tsai HC, Mullane KM, Sutton SH, Stevens P. Accelerated neutrophil apoptosis in the acquired immunodeficiency syndrome. J Clin Investig. 1996;98(12):2714–9.PubMedPubMedCentralCrossRef
92.
Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin Infect Dis. 2000;30(2):256–60.PubMedCrossRef
93.
Olinger GG, Saifuddin M, Spear GT. CD4-Negative cells bind human immunodeficiency virus type 1 and efficiently transfer virus to T cells. J Virol. 2000;74(18):8550–7.PubMedPubMedCentralCrossRef
94.
Biswas P, Mantelli B, Sica A, Malnati M, Panzeri C, Saccani A, et al. Expression of CD4 on human peripheral blood neutrophils. Blood. 2003;101(11):4452–6.PubMedCrossRef
95.
Gabali AM, Anzinger JJ, Spear GT, Thomas LL. Activation by inflammatory stimuli increases neutrophil binding of human immunodeficiency virus type 1 and subsequent infection of lymphocytes. J Virol. 2004;78(19):10833–6.PubMedPubMedCentralCrossRef
96.
Elbim C, Prevot MH, Bouscarat F, Franzini E, Chollet-Martin S, Hakim J, et al. Polymorphonuclear neutrophils from human immunodeficiency virus-infected patients show enhanced activation, diminished fMLP-induced L-selectin shedding, and an impaired oxidative burst after cytokine priming. Blood. 1994;84(8):2759–66.PubMed
97.
Gasperini S, Zambello R, Agostini C, Trentin L, Tassinari C, Cadrobbi P, et al. Impaired cytokine production by neutrophils isolated from patients with AIDS. Aids. 1998;12(4):373–9.PubMedCrossRef
98.
Heit B, Jones G, Knight D, Antony JM, Gill MJ, Brown C, et al. HIV and other lentiviral infections cause defects in neutrophil chemotaxis, recruitment, and cell structure: immunorestorative effects of granulocyte-macrophage colony-stimulating factor. J Immunol. 2006;177(9):6405–14.PubMedCrossRef
99.
Kubes P, Heit B, van Marle G, Johnston JB, Knight D, Khan A, et al. In vivo impairment of neutrophil recruitment during lentivirus infection. J Immunol. 2003;171(9):4801–8.PubMedCrossRef
100.
Roilides E, Mertins S, Eddy J, Walsh TJ, Pizzo PA, Rubin M. Impairment of neutrophil chemotactic and bactericidal function in children infected with human immunodeficiency virus type 1 and partial reversal after in vitro exposure to granulocyte-macrophage colony-stimulating factor. J Pediatr. 1990;117(4):531–40.PubMedCrossRef
101.
Coffey MJ, Phare SM, George S, Peters-Golden M, Kazanjian PH. Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils. J Clin Investig. 1998;102(4):663–70.PubMedPubMedCentralCrossRef
102.
Pugliese A, Vidotto V, Beltramo T, Torre D. Phagocytic activity in human immunodeficiency virus type 1 infection. Clin Diagn Lab Immunol. 2005;12(8):889–95.PubMedPubMedCentral
103.
Engelich G, Wright DG, Hartshorn KL. Acquired disorders of phagocyte function complicating medical and surgical illnesses. Clin Infect Dis. 2001;33(12):2040–8.PubMedCrossRef
104.
Pitrak DL. Neutrophil deficiency and dysfunction in HIV-infected patients. Am J Health Syst Pharm. 1999;56(Suppl 5):S9–16.PubMed
105.
Elbim C, Pillet S, Prevost MH, Preira A, Girard PM, Rogine N, et al. The role of phagocytes in HIV-related oxidative stress. J Clin Virol. 2001;20(3):99–109.PubMedCrossRef
106.
Salmen S, Montilla D, London M, Velazquez D, Berrueta L. Analysis of p22-phox and p47-phox subcellular localization and distribution in neutrophils from human immunodeficiency virus (HIV) infected patients. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. 2012;64(1):40–51.PubMed
107.
Saitoh T, Komano J, Saitoh Y, Misawa T, Takahama M, Kozaki T, et al. Neutrophil extracellular traps mediate a host defense response to human immunodeficiency virus-1. Cell Host Microbe. 2012;12(1):109–16.PubMedCrossRef
108.
Cloke T, Munder M, Bergin P, Herath S, Modolell M, Taylor G, et al. Phenotypic alteration of neutrophils in the blood of HIV seropositive patients. PLoS ONE. 2013;8(9):e72034.PubMedPubMedCentralCrossRef
109.
Bowers NL, Helton ES, Huijbregts RP, Goepfert PA, Heath SL, Hel Z. Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway. PLoS Pathog. 2014;10(3):e1003993.PubMedPubMedCentralCrossRef
110.
Rothenberg ME, Pomerantz JL, Owen WF Jr, Avraham S, Soberman RJ, Austen KF, et al. Characterization of a human eosinophil proteoglycan, and augmentation of its biosynthesis and size by interleukin 3, interleukin 5, and granulocyte/macrophage colony stimulating factor. J Biol Chem. 1988;263(27):13901–8.PubMed
111.
Greer JP. In: Greer JP, Arber DA, Glader B, List AF, Means Jr RT, Paraskevas F, et al., editors. Wintrobe's clinical hematology. 13th ed. Philadelphia: Wolters Kluwer Lippincott Williams & Wilkins Health; 2014. p. 2278.
112.
Cohen AJ, Steigbigel RT. Eosinophilia in patients infected with human immunodeficiency virus. J Infect Dis. 1996;174(3):615–8.PubMedCrossRef
113.
Sivaram M, White A, Radcliffe KW. Eosinophilia: clinical significance in HIV-infected individuals. Int J STD AIDS. 2012;23(9):635–8.PubMedCrossRef
114.
Paboriboune P, Phoumindr N, Borel E, Sourinphoumy K, Phaxayaseng S, Luangkhot E, et al. Intestinal parasitic infections in HIV-infected patients, Lao People’s Democratic Republic. PLoS ONE. 2014;9(3):e91452.PubMedPubMedCentralCrossRef
115.
Skiest DJ, Keiser P. Clinical significance of eosinophilia in HIV-infected individuals. Am J Med. 1997;102(5):449–53.PubMedCrossRef
116.
Pavie J, Menotti J, Porcher R, Donay JL, Gallien S, Sarfati C, et al. Prevalence of opportunistic intestinal parasitic infections among HIV-infected patients with low CD4 cells counts in France in the combination antiretroviral therapy era. Int J Infect Dis. 2012;16(9):e677–9.PubMedCrossRef
117.
Lucey DR, Dorsky DI, Nicholson-Weller A, Weller PF. Human eosinophils express CD4 protein and bind human immunodeficiency virus 1 gp120. J Exp Med. 1989;169(1):327–32.PubMedCrossRef
118.
Nagase H, Miyamasu M, Yamaguchi M, Fujisawa T, Ohta K, Yamamoto K, et al. Expression of CXCR4 in eosinophils: functional analyses and cytokine-mediated regulation. J Immunol. 2000;164(11):5935–43.PubMedCrossRef
119.
Colebunders R, Van Den Eynde C, Tolo A, Fleerackers Y, Vanham G, Kestens L, et al. Eosinophilia in patients infected with human immunodeficiency virus. J Infect Dis. 1997;175(5):1283.PubMedCrossRef
120.
121.
Kawakami T, Galli SJ. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol. 2002;2(10):773–86.PubMedCrossRef
122.
123.
Israel-Biet D, Labrousse F, Tourani JM, Sors H, Andrieu JM, Even P. Elevation of IgE in HIV-infected subjects: a marker of poor prognosis. J Allergy Clin Immunol. 1992;89(1 Pt 1):68–75.PubMedCrossRef
124.
Lucey DR, Zajac RA, Melcher GP, Butzin CA, Boswell RN. Serum IgE levels in 622 persons with human immunodeficiency virus infection: IgE elevation with marked depletion of CD4+ T-cells. AIDS Res Hum Retrovir. 1990;6(4):427–9.PubMedCrossRef
125.
Florio G, Petraroli A, Patella V, Triggiani M, Marone G. The immunoglobulin superantigen-binding site of HIV-1 gp120 activates human basophils. Aids. 2000;14(8):931–8.PubMedCrossRef
126.
Miadonna A, Leggieri E, Tedeschi A, Lazzarin A, Chianura L, Froldi M, et al. Enhanced basophil releasability in subjects infected with human immunodeficiency virus. Clin Immunol Immunopathol. 1990;54(2):237–46.PubMedCrossRef
127.
Patella V, Florio G, Petraroli A, Marone G. HIV-1 gp120 induces IL-4 and IL-13 release from human Fc epsilon RI + cells through interaction with the VH3 region of IgE. J Immunol. 2000;164(2):589–95.PubMedCrossRef
128.
Pedersen M, Nielsen CM, Permin H. HIV antigen-induced release of histamine from basophils from HIV infected patients. Mechanism and relation to disease progression and immunodeficiency. Allergy. 1991;46(3):206–12.PubMedCrossRef
129.
Albini A, Ferrini S, Benelli R, Sforzini S, Giunciuglio D, Aluigi MG, et al. HIV-1 Tat protein mimicry of chemokines. Proc Nat Acad Sci USA. 1998;95(22):13153–8.PubMedPubMedCentralCrossRef
130.
de Paulis A, De Palma R, Di Gioia L, Carfora M, Prevete N, Tosi G, et al. Tat protein is an HIV-1-encoded beta-chemokine homolog that promotes migration and up-regulates CCR3 expression on human Fc epsilon RI+ cells. J Immunol. 2000;165(12):7171–9.PubMedCrossRef
131.
Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993;328(23):1670–4.PubMedCrossRef
132.
Kaplan MH, Sadick N, McNutt NS, Meltzer M, Sarngadharan MG, Pahwa S. Dermatologic findings and manifestations of acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol. 1987;16(3 Pt 1):485–506.PubMedCrossRef
133.
Klein SA, Dobmeyer JM, Dobmeyer TS, Pape M, Ottmann OG, Helm EB, et al. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS. 1997;11(9):1111–8.PubMedCrossRef
134.
Maggi E, Mazzetti M, Ravina A, Annunziato F, de Carli M, Piccinni MP, et al. Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. Science. 1994;265(5169):244–8.PubMedCrossRef
135.
Bannert N, Farzan M, Friend DS, Ochi H, Price KS, Sodroski J, et al. Human Mast cell progenitors can be infected by macrophagetropic human immunodeficiency virus type 1 and retain virus with maturation in vitro. J Virol. 2001;75(22):10808–14.PubMedPubMedCentralCrossRef
136.
Li Y, Li L, Wadley R, Reddel SW, Qi JC, Archis C, et al. Mast cells/basophils in the peripheral blood of allergic individuals who are HIV-1 susceptible due to their surface expression of CD4 and the chemokine receptors CCR3, CCR5, and CXCR4. Blood. 2001;97(11):3484–90.PubMedCrossRef
137.
Sundstrom JB, Ellis JE, Hair GA, Kirshenbaum AS, Metcalfe DD, Yi H, et al. Human tissue mast cells are an inducible reservoir of persistent HIV infection. Blood. 2007;109(12):5293–300.PubMedCrossRef
138.
Sundstrom JB, Hair GA, Ansari AA, Secor WE, Gilfillan AM, Metcalfe DD, et al. IgE-FcepsilonRI interactions determine HIV coreceptor usage and susceptibility to infection during ontogeny of mast cells. J Immunol. 2009;182(10):6401–9.PubMedPubMedCentralCrossRef
139.
140.
Nelson AM, Auerbach A, Man YG. Failure to detect active virus replication in mast cells at various tissue sites of HIV patients by immunohistochemistry. Int J Biol Sci. 2009;5(6):603–10.PubMedPubMedCentralCrossRef
141.
Jiang AP, Jiang JF, Wei JF, Guo MG, Qin Y, Guo QQ, et al. Human mucosal mast cells capture HIV-1 and mediate viral trans-infection of CD4+ T cells. J Virol. 2015;90(6):2928–37.PubMedCrossRef
142.
Jiang AP, Jiang JF, Guo MG, Jin YM, Li YY, Wang JH. Human blood-circulating basophils capture HIV-1 and mediate viral trans-infection of CD4 + T cells. J Virol. 2015;89(15):8050–62.PubMedPubMedCentralCrossRef
143.
Iwasaki H, Akashi K. Hematopoietic developmental pathways: on cellular basis. Oncogene. 2007;26(47):6687–96.PubMedCrossRef
144.
Lazarevic V, Glimcher LH, Lord GM. T-bet: a bridge between innate and adaptive immunity. Nat Rev Immunol. 2013;13(11):777–89.PubMedCrossRef
145.
Eberl G, Di Santo JP, Vivier E. The brave new world of innate lymphoid cells. Nat Immunol. 2015;16(1):1–5.PubMedCrossRef
146.
Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells—a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13(2):145–9.PubMedCrossRef
147.
Vivier E, van de Pavert SA, Cooper MD, Belz GT. The evolution of innate lymphoid cells. Nat Immunol. 2016;17(7):790–4.PubMedCrossRef
148.
Kloverpris HN, Kazer SW, Mjosberg J, Mabuka JM, Wellmann A, Ndhlovu Z, et al. Innate lymphoid cells are depleted irreversibly during acute HIV-1 infection in the absence of viral suppression. Immunity. 2016;44(2):391–405.PubMedCrossRef
149.
150.
151.
Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, Waring MT, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood. 2005;106(10):3366–9.PubMedCrossRef
152.
Kuri-Cervantes L, de Oca GS, Avila-Rios S, Hernandez-Juan R, Reyes-Teran G. Activation of NK cells is associated with HIV-1 disease progression. J Leukoc Biol. 2014;96(1):7–16.PubMedCrossRef
153.
Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633–40.PubMedCrossRef
154.
Hu PF, Hultin LE, Hultin P, Hausner MA, Hirji K, Jewett A, et al. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10(3):331–40.PubMed
155.
Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E, et al. Characterization of CD56−/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA. 2005;102(8):2886–91.PubMedPubMedCentralCrossRef
156.
Vieillard V, Fausther-Bovendo H, Samri A, Debre P. French asymptomatiques a long terme A-COSG. Specific phenotypic and functional features of natural killer cells from HIV-infected long-term nonprogressors and HIV controllers. J Acquir Immune Defic Syndr. 2010;53(5):564–73.PubMed
157.
Bernstein HB, Wang G, Plasterer MC, Zack JA, Ramasastry P, Mumenthaler SM, et al. CD4 + NK cells can be productively infected with HIV, leading to downregulation of CD4 expression and changes in function. Virology. 2009;387(1):59–66.PubMedPubMedCentralCrossRef
158.
Mavilio D, Benjamin J, Daucher M, Lombardo G, Kottilil S, Planta MA, et al. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Nat Acad Sci USA. 2003;100(25):15011–6.PubMedPubMedCentralCrossRef
159.
Lichtfuss GF, Cheng WJ, Farsakoglu Y, Paukovics G, Rajasuriar R, Velayudham P, et al. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J Immunol. 2012;189(3):1491–9.PubMedCrossRef
160.
Brockman MA, Kwon DS, Tighe DP, Pavlik DF, Rosato PC, Sela J, et al. IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood. 2009;114(2):346–56.PubMedPubMedCentralCrossRef
161.
Parato KG, Kumar A, Badley AD, Sanchez-Dardon JL, Chambers KA, Young CD, et al. Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10. AIDS. 2002;16(9):1251–6.PubMedCrossRef
162.
Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, Nguyen NV, et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol. 2003;171(11):5663–7.PubMedCrossRef
163.
Vieillard V, Strominger JL, Debre P. NK cytotoxicity against CD4 + T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc Nat Acad Sci USA. 2005;102(31):10981–6.PubMedPubMedCentralCrossRef
164.
Ward J, Bonaparte M, Sacks J, Guterman J, Fogli M, Mavilio D, et al. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood. 2007;110(4):1207–14.PubMedPubMedCentralCrossRef
165.
Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet. 2002;31(4):429–34.PubMed
166.
Kramski M, Stratov I, Kent SJ. The role of HIV-specific antibody-dependent cellular cytotoxicity in HIV prevention and the influence of the HIV-1 Vpu protein. AIDS. 2015;29(2):137–44.PubMedCrossRef
167.
Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS. 2009;23(8):897–906.PubMedPubMedCentralCrossRef
168.
169.
Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Ann Rev Immunol. 2007;25:297–336.CrossRef
170.
Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol. 2009;86(3):513–28.PubMedPubMedCentralCrossRef
171.
Motsinger A, Haas DW, Stanic AK, Van Kaer L, Joyce S, Unutmaz D. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J Exp Med. 2002;195(7):869–79.PubMedPubMedCentralCrossRef
172.
Fernandez CS, Kelleher AD, Finlayson R, Godfrey DI, Kent SJ. NKT cell depletion in humans during early HIV infection. Immunol Cell Biol. 2014;92(7):578–90.PubMedCrossRef
173.
Sandberg JK, Fast NM, Palacios EH, Fennelly G, Dobroszycki J, Palumbo P, et al. Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol. 2002;76(15):7528–34.PubMedPubMedCentralCrossRef
174.
175.
Yang OO, Wilson SB, Hultin LE, Detels R, Hultin PM, Ibarrondo FJ, et al. Delayed reconstitution of CD4 + iNKT cells after effective HIV type 1 therapy. AIDS Res Hum Retrovir. 2007;23(7):913–22.PubMedCrossRef
176.
Unutmaz D. NKT cells and HIV infection. Microbes and infection/Institut Pasteur. 2003;5(11):1041–7.CrossRef
177.
178.
Poccia F, Gougeon ML, Bonneville M, Lopez-Botet M, Moretta A, Battistini L, et al. Innate T-cell immunity to nonpeptidic antigens. Immunol Today. 1998;19(6):253–6.PubMedCrossRef
179.
Poccia F, Wallace M, Colizzi V, Malkovsky M. Possible protective and pathogenic roles of gamma delta T lymphocytes in HIV-infections (Review). Int J Mol Med. 1998;1(2):409–13.PubMed
180.
Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197(2):163–8.PubMedPubMedCentralCrossRef
181.
Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity. 2009;31(2):184–96.PubMedCrossRef
182.
Poccia F, Boullier S, Lecoeur H, Cochet M, Poquet Y, Colizzi V, et al. Peripheral V gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons. J Immunol. 1996;157(1):449–61.PubMed
183.
Autran B, Triebel F, Katlama C, Rozenbaum W, Hercend T, Debre P. T cell receptor gamma/delta + lymphocyte subsets during HIV infection. Clin Exp Immunol. 1989;75(2):206–10.PubMedPubMedCentral
184.
Chia WK, Freedman J, Li X, Salit I, Kardish M, Read SE. Programmed cell death induced by HIV type 1 antigen stimulation is associated with a decrease in cytotoxic T lymphocyte activity in advanced HIV type 1 infection. AIDS Res Hum Retrovir. 1995;11(2):249–56.PubMedCrossRef
185.
Li H, Pauza CD. HIV envelope-mediated, CCR5/alpha4beta7-dependent killing of CD4-negative gammadelta T cells which are lost during progression to AIDS. Blood. 2011;118(22):5824–31.PubMedPubMedCentralCrossRef
186.
Li H, Peng H, Ma P, Ruan Y, Su B, Ding X, et al. Association between Vgamma2Vdelta2 T cells and disease progression after infection with closely related strains of HIV in China. Clin Infect Dis. 2008;46(9):1466–72.PubMedPubMedCentralCrossRef
187.
Wallace M, Scharko AM, Pauza CD, Fisch P, Imaoka K, Kawabata S, et al. Functional gamma delta T-lymphocyte defect associated with human immunodeficiency virus infections. Mol Med. 1997;3(1):60–71.PubMedPubMedCentral
188.
Sacchi A, Tempestilli M, Turchi F, Agrati C, Casetti R, Cimini E, et al. CD3zeta down-modulation may explain Vgamma9Vdelta2 T lymphocyte anergy in HIV-infected patients. J Infect Dis. 2009;199(3):432–6.PubMedCrossRef
189.
Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, et al. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood. 2010;116(10):1726–33.PubMedPubMedCentralCrossRef
190.
Brunetta E, Hudspeth KL, Mavilio D. Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes. J Leukoc Biol. 2010;88(6):1119–30.PubMedCrossRef
191.
Li H, Chaudhry S, Poonia B, Shao Y, Pauza CD. Depletion and dysfunction of Vgamma2Vdelta2 T cells in HIV disease: mechanisms, impacts and therapeutic implications. Cell Mol Immunol. 2013;10(1):42–9.PubMedCrossRef
192.
Martini F, Poccia F, Goletti D, Carrara S, Vincenti D, D’Offizi G, et al. Acute human immunodeficiency virus replication causes a rapid and persistent impairment of Vgamma9Vdelta2 T cells in chronically infected patients undergoing structured treatment interruption. J Infect Dis. 2002;186(6):847–50.PubMedCrossRef
193.
Nilssen DE, Muller F, Oktedalen O, Froland SS, Fausa O, Halstensen TS, et al. Intraepithelial gamma/delta T cells in duodenal mucosa are related to the immune state and survival time in AIDS. J Virol. 1996;70(6):3545–50.PubMedPubMedCentral
194.
Espindola MS, Frantz FG, Soares LS, Masson AP, Tefe-Silva C, Bitencourt CS, et al. Combined immunization using DNA-Sm14 and DNA-Hsp65 increases CD8+ memory T cells, reduces chronic pathology and decreases egg viability during Schistosoma mansoni infection. BMC Infect Dis. 2014;14:263.PubMedPubMedCentralCrossRef
195.
CobosJimenez V, Wit FW, Joerink M, Maurer I, Harskamp AM, Schouten J, et al. T-cell activation independently associates with immune senescence in HIV-infected recipients of long-term antiretroviral treatment. J Infect Dis. 2016;214(2):216–25.CrossRef
196.
Wada NI, Jacobson LP, Margolick JB, Breen EC, Macatangay B, Penugonda S, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS. 2015;29(4):463–71.PubMedPubMedCentralCrossRef
197.
198.
199.
Zapata HJ, Shaw AC. Aging of the human innate immune system in HIV infection. Curr Opin Immunol. 2014;29:127–36.PubMedCrossRef
Metadata
Title
HIV infection: focus on the innate immune cells
Authors
Milena S. Espíndola
Luana S. Soares
Leonardo J. Galvão-Lima
Fabiana A. Zambuzi
Maira C. Cacemiro
Verônica S. Brauer
Fabiani G. Frantz
Publication date
01-12-2016
Publisher
Springer US
Published in
Immunologic Research / Issue 5-6/2016
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-016-8862-2

Other articles of this Issue 5-6/2016

Immunologic Research 5-6/2016 Go to the issue

Brief Report

TRIM5 gene polymorphisms in HIV-1-infected patients and healthy controls from Northeastern Brazil

Original Article

Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis

Review

The role of adenosinergic pathway in human autoimmune diseases

Brief Report

Clinical association of mixed connective tissue disease and granulomatosis with polyangiitis: a case report and systematic screening of anti-U1RNP and anti-PR3 auto-antibody double positivity in ten European hospitals

Original Article

Suppression of interleukin 17 contributes to the immunomodulatory effects of adipose-derived stem cells in a murine model of systemic lupus erythematosus

Original Article

Effect of continuous positive airway pressure (CPAP) therapy on IL-23 in patients with obstructive sleep apnea